In the past week, CERO stock has gone down by -13.30%, with a monthly decline of -1.28% and a quarterly plunge of -36.49%. The volatility ratio for the week is 6.56%, and the volatility levels for the last 30 days are 22.38% for CERo Therapeutics Holdings Inc The simple moving average for the past 20 days is -3.12% for CERO’s stock, with a -90.82% simple moving average for the past 200 days.
Is It Worth Investing in CERo Therapeutics Holdings Inc (NASDAQ: CERO) Right Now?
CERO has 36-month beta value of 0.50. Analysts have mixed views on the stock, with 1 analysts rating it as a “buy”, 1 as “overweight”, 1 as “hold”, and 0 as “sell”.
The public float for CERO is 0.36M, and currently, short sellers hold a 8.90% ratio of that float. The average trading volume of CERO on July 04, 2025 was 1.16M shares.
CERO stock’s latest price update
CERo Therapeutics Holdings Inc (NASDAQ: CERO)’s stock price has decreased by -2.11% compared to its previous closing price of $9.46. However, the company has seen a -13.30% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-06-23 that SOUTH SAN FRANSCISCO, Calif., June 23, 2025 (GLOBE NEWSWIRE) — CERo Therapeutics Holdings, Inc. (Nasdaq: CERO) (“CERo” or the “Company”), an immunotherapy company developing the next generation of engineered T cell therapeutics targeting TIM4L with phagocytic mechanisms, today announces the completion of the initial evaluation of the first patient in its Phase 1 clinical trial of lead compound CER-1236. Following an evaluation from the trial’s Dose Escalation Safety Committee, preliminary results show that the patient demonstrated no dose limiting toxicity. The Company anticipates dosing the second patient in the cohort shortly.
Analysts’ Opinion of CERO
Many brokerage firms have already submitted their reports for CERO stocks, with D. Boral Capital repeating the rating for CERO by listing it as a “Buy”. The predicted price for CERO in the upcoming period, according to D. Boral Capital is $30 based on the research report published on June 23, 2025 of the current year 2025.
CERO Trading at -21.57% from the 50-Day Moving Average
After a stumble in the market that brought CERO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -98.97% of loss for the given period.
Volatility was left at 22.38%, however, over the last 30 days, the volatility rate increased by 6.56%, as shares surge +2.89% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -38.90% lower at present.
During the last 5 trading sessions, CERO fell by -13.30%, which changed the moving average for the period of 200-days by -95.03% in comparison to the 20-day moving average, which settled at $9.56. In addition, CERo Therapeutics Holdings Inc saw -98.31% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CERO starting from YK Bioventures Opportunities G, who sold 2,998,908 shares at the price of $0.06 back on Dec 13 ’24. After this action, YK Bioventures Opportunities G now owns 13,005,169 shares of CERo Therapeutics Holdings Inc, valued at $179,934 using the latest closing price.
YK Bioventures Opportunities G, the 10% Owner of CERo Therapeutics Holdings Inc, sale 1,614,541 shares at $0.07 during a trade that took place back on Dec 12 ’24, which means that YK Bioventures Opportunities G is holding 16,004,077 shares at $113,018 based on the most recent closing price.
Stock Fundamentals for CERO
The total capital return value is set at -125.55%. Equity return is now at value -4090.08%, with -114.10% for asset returns.
Based on CERo Therapeutics Holdings Inc (CERO), the company’s capital structure generated 1.32 points at debt to capital in total, while cash flow to debt ratio is standing at -3.77. The debt to equity ratio resting at -4.15. The interest coverage ratio of the stock is 1723.6.
Currently, EBITDA for the company is -6.57 million with net debt to EBITDA at 0.27. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.73.
Conclusion
To put it simply, CERo Therapeutics Holdings Inc (CERO) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
